Shares of Human Genome Sciences Inc., the maker of an experimental lupus drug, rose for a sixth straight day today on market speculation that GlaxoSmithKline P.L.C. may pay as much as $30 per share to buy it, according to several published reports.
Copyright PHILY - Philly.com
